Viridian noted in a Chart of the Week published in November 2022 that increased “consolidation is inevitable” in the Cannabis industry. What does the latest data show?
The green bars in the graph show data from BDSA that Viridian presented at the Green Market Finance Summit at NECANN on March 22. The orange line is an alternate calculation based on company financial statements. Although both data sets show a higher concentration level in 2023 than 2020, the recent direction differs. Which one is correct, and what is the likely future direction?
The BDSA data shows the share of sales by the top 20 brand houses each year. Note that the top 20 may be different each year. BDSA aggregated all retail sales of the brands associated with a brand house. For example, all of the retail sales by Green Thumb brands are added, whether GTI makes the retail sale at one of its dispensaries or someone else sells the product purchased from Green Thumbs on the wholesale market. This approach puts everything on a retail basis.
The financial statement calculation is more straightforward: aggregating the highest twenty company revenues each year divided by the Statista total retail sales number. This approach, however, is biased downward for two reasons. The total revenue for each company is a combination of retail and wholesale revenue, and this approach neglects to include the retail markup on the wholesale sales. The Viridian database also includes only public companies; large brands like Stiizy are not represented. We conclude that the BDSA approach is superior, and its demonstration of increased consolidation in recent years is likely accurate.
Further increases in concentration are likely. The beer industry is a good analog. Like in cannabis, there are over 10,000 small craft beer companies, but the top five account for more than 60% of sales. Wine is another interesting example. There are over 1800 brands of wine sold in the U.S. Still, five companies (E&J Gallo, The Wine Group, Constellation Brands, Tranchero Family Estates, and Treasury Wine Estates) own the brands that make up over 60% of sales.
Why did both wine and beer consolidate to such a degree? Economies of scale in production, packaging, distribution, and marketing drove the consolidation, and those same factors will drive consolidation in cannabis.
As capital markets reopen after rescheduling, larger, more liquid companies will be the first to benefit from incremental investment in the industry. Their cost of capital advantage will make it easier for them to grow relative to their smaller competitors. Full legalization, when and if it happens, will accelerate consolidation pressures. Larger regional cultivation and production facilities with significant cost advantages will likely emerge. Tremendous expenditures will be required to build brand awareness and conduct nationwide advertising programs. The largest MSOs today are tiny companies in the landscape of American commerce. Either they will grow much larger or be acquired by larger companies from outside the industry. There will always be thousands of small cannabis companies, and those with superior marketing skills to establish niche positions with differentiated products will thrive, while those that do not disappear.
The Viridian Capital Chart of the Week highlights key investment, valuation and M&A trends taken from the Viridian Cannabis Deal Tracker.
The Viridian Cannabis Deal Tracker provides the market intelligence that cannabis companies, investors, and acquirers utilize to make informed decisions regarding capital allocation and M&A strategy. The Deal Tracker is a proprietary information service that monitors capital raise and M&A activity in the legal cannabis, CBD, and psychedelics industries. Each week the Tracker aggregates and analyzes all closed deals and segments each according to key metrics:
-
Deals by Industry Sector (To track the flow of capital and M&A Deals by one of 12 Sectors - from Cultivation to Brands to Software)
-
Deal Structure (Equity/Debt for Capital Raises, Cash/Stock/Earnout for M&A) Status of the company announcing the transaction (Public vs. Private)
-
Principals to the Transaction (Issuer/Investor/Lender/Acquirer) Key deal terms (Pricing and Valuation)
-
Key Deal Terms (Deal Size, Valuation, Pricing, Warrants, Cost of Capital)
-
Deals by Location of Issuer/Buyer/Seller (To Track the Flow of Capital and M&A Deals by State and Country)
-
Credit Ratings (Leverage and Liquidity Ratios)
Since its inception in 2015, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,500 capital raises and 1,000 M&A transactions totaling over $50 billion in aggregate value.
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.